Pei Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pei Wei has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Zhiyong Wang
Department of Immunology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China
12 shared publicationsMin Wang
Department of Pharmaceutics, Zhuhai Campus of Zunyi Medical University, Zhuhai, China
6 shared publicationsMao Lin
Department of Physiology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China
4 shared publicationsJiaqi Li
Department of Immunology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China
2 shared publicationsJinjin Guo
Department of Immunology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China
2 shared publications- Ling-Chun Kong
The Second Hospital of Shanxi Medical University, Taiyuan, China
2 shared publications
Latest Publications
- Open Access
- 5 August 2025
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 24 (1)
Low-Dose Celastrol Modulates IL-6 Secretion to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with sorafenib being a key treatment option. However, resistance to sorafenib often develops, limiting its effectiveness. Celastrol, a phytochemical derived from Tripterygium wilfordii, has shown potential in enhancing anti-tumor drug efficacy, but concerns about toxicity and clinical applicability remain. Objectives: This study investigated whether celastrol at plasma-achievable concentrations could modulate sorafenib resistance in HCC cells in-vitro. Methods: Cytotoxicity experiments were conducted using MTT assays to assess the effects of celastrol and sorafenib on HCC cells and normal hepatocytes. Immunofluorescence (IF) and ELISA assays were employed to measure IL-6 expression and secretion in HCC cells. Bioinformatics analyses were performed on publicly available gene expression data to identify pathways associated with sorafenib resistance. Conditioned media (CM) from treated cells were used to evaluate the impact of celastrol on sorafenib sensitivity in untreated HCC cells. Results: High concentrations of celastrol enhanced sorafenib’s inhibitory effects on HCC cells but also increased cytotoxicity in normal hepatocytes. Low concentrations of celastrol mitigated sorafenib-induced tumor cell inhibition but reversed acquired sorafenib resistance without increasing cytotoxicity in normal hepatocytes. The reversal of resistance by low-dose celastrol was associated with the inhibition of sorafenib-induced IL-6 secretion. The CM from tumor cells treated with low-dose celastrol plus sorafenib increased the sensitivity of untreated tumor cells to sorafenib, an effect reversed by the addition of exogenous IL-6 or by using IL-6-neutralizing antibodies. Conclusions: Low-dose celastrol can reverse sorafenib resistance in HCC cells by inhibiting sorafenib-induced IL-6 secretion, without increasing hepatotoxicity.
- 5 August 2025
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 24 (1)
Open AccessLow-Dose Celastrol Modulates IL-6 Secretion to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with sorafenib being a key treatment option. However, resistance to sorafenib often develops, limiting its effectiveness. Celastrol, a phytochemical derived from Tripterygium wilfordii, has shown potential in enhancing anti-tumor drug efficacy, but concerns about toxicity and clinical applicability remain. Objectives: This study investigated whether celastrol at plasma-achievable concentrations could modulate sorafenib resistance in HCC cells in-vitro. Methods: Cytotoxicity experiments were conducted using MTT assays to assess the effects of celastrol and sorafenib on HCC cells and normal hepatocytes. Immunofluorescence (IF) and ELISA assays were employed to measure IL-6 expression and secretion in HCC cells. Bioinformatics analyses were performed on publicly available gene expression data to identify pathways associated with sorafenib resistance. Conditioned media (CM) from treated cells were used to evaluate the impact of celastrol on sorafenib sensitivity in untreated HCC cells. Results: High concentrations of celastrol enhanced sorafenib’s inhibitory effects on HCC cells but also increased cytotoxicity in normal hepatocytes. Low concentrations of celastrol mitigated sorafenib-induced tumor cell inhibition but reversed acquired sorafenib resistance without increasing cytotoxicity in normal hepatocytes. The reversal of resistance by low-dose celastrol was associated with the inhibition of sorafenib-induced IL-6 secretion. The CM from tumor cells treated with low-dose celastrol plus sorafenib increased the sensitivity of untreated tumor cells to sorafenib, an effect reversed by the addition of exogenous IL-6 or by using IL-6-neutralizing antibodies. Conclusions: Low-dose celastrol can reverse sorafenib resistance in HCC cells by inhibiting sorafenib-induced IL-6 secretion, without increasing hepatotoxicity.
- 1 August 2025
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 523 (1) , 419-423
Biphasic Effects of bFGF Blockade on Lung Cancer Cell Invasion
Basic fibroblast growth factor (bFGF) is a potent mitogen implicated in tumor progression, yet its precise role in cancer cell invasion remains multifaceted. Here, we unveiled a dose-dependent, biphasic regulatory effect of bFGF blockade on the invasiveness of lung cancer cells. Using a neutralizing monoclonal antibody against bFGF (bFGF Ab), we demonstrated that moderate neutralization of bFGF inhibited tumor cell invasion. Conversely, excessive bFGF blockade paradoxically enhanced the invasive capacity of lung cancer cells. Furthermore, we showed that the divergent invasive phenotypes arising from varying degrees of bFGF inhibition were mediated by altered vascular endothelial growth factor (VEGF) secretion. These findings underscore the critical importance of dose optimization in bFGF-targeted therapies, particularly concerning their impact on lung cancer invasiveness, and identify VEGF as a key mediator of these effects.
- 1 August 2025
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 523 (1) , 419-423
Biphasic Effects of bFGF Blockade on Lung Cancer Cell Invasion
Basic fibroblast growth factor (bFGF) is a potent mitogen implicated in tumor progression, yet its precise role in cancer cell invasion remains multifaceted. Here, we unveiled a dose-dependent, biphasic regulatory effect of bFGF blockade on the invasiveness of lung cancer cells. Using a neutralizing monoclonal antibody against bFGF (bFGF Ab), we demonstrated that moderate neutralization of bFGF inhibited tumor cell invasion. Conversely, excessive bFGF blockade paradoxically enhanced the invasive capacity of lung cancer cells. Furthermore, we showed that the divergent invasive phenotypes arising from varying degrees of bFGF inhibition were mediated by altered vascular endothelial growth factor (VEGF) secretion. These findings underscore the critical importance of dose optimization in bFGF-targeted therapies, particularly concerning their impact on lung cancer invasiveness, and identify VEGF as a key mediator of these effects.
- 13 July 2024
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 517 (1) , 285-290
Basic Fibroblast Growth Factor Accumulation in Culture Medium Masks the Direct Antitumor Effect of Anti-VEGF Agent Bevacizumab
The direct antitumor effect of bevacizumab (BEV) has long been debated. Evidence of the direct antitumor activities of drugs are mainly obtained from in vitro experiments, which are greatly affected by experimental conditions. In this study, we evaluated the effect of BEV-containing medium renewal on the results of in vitro cytotoxicity experiments in A549 and U251 cancer cells. We observed starkly different results between the experiments with and without BEV-containing medium renewal. Specifically, BEV inhibited the tumor cell growth in the timely replacement with a BEV-containing medium but promoted tumor cell growth without medium renewal. Meanwhile, compared with the control, a significant basic fibroblast growth factor (bFGF) accumulation in the supernatant was observed in the group without medium renewal but none in that with replaced medium. Furthermore, bFGF neutralization partially reversed the pro-proliferative effect of BEV in the medium non-renewed group, while exogenous bFGF attenuated the tumor cell growth inhibition of BEV in the medium-renewed group. Our data explain the controversy over the direct antitumor effect of BEV in different studies from the perspective of the compensatory autocrine cytokines in tumor cells.
- 13 July 2024
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 517 (1) , 285-290
Basic Fibroblast Growth Factor Accumulation in Culture Medium Masks the Direct Antitumor Effect of Anti-VEGF Agent Bevacizumab
The direct antitumor effect of bevacizumab (BEV) has long been debated. Evidence of the direct antitumor activities of drugs are mainly obtained from in vitro experiments, which are greatly affected by experimental conditions. In this study, we evaluated the effect of BEV-containing medium renewal on the results of in vitro cytotoxicity experiments in A549 and U251 cancer cells. We observed starkly different results between the experiments with and without BEV-containing medium renewal. Specifically, BEV inhibited the tumor cell growth in the timely replacement with a BEV-containing medium but promoted tumor cell growth without medium renewal. Meanwhile, compared with the control, a significant basic fibroblast growth factor (bFGF) accumulation in the supernatant was observed in the group without medium renewal but none in that with replaced medium. Furthermore, bFGF neutralization partially reversed the pro-proliferative effect of BEV in the medium non-renewed group, while exogenous bFGF attenuated the tumor cell growth inhibition of BEV in the medium-renewed group. Our data explain the controversy over the direct antitumor effect of BEV in different studies from the perspective of the compensatory autocrine cytokines in tumor cells.
- Open Access
- 23 April 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1394878
Direct antitumor activity of bevacizumab: an overlooked mechanism?
- 23 April 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1394878
Open AccessDirect antitumor activity of bevacizumab: an overlooked mechanism?
- Open Access
- 9 January 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1322305
Nanomaterial-induced pyroptosis: a cell type-specific perspective
This review presents the advancements in nanomaterial (NM)-induced pyroptosis in specific types of cells. We elucidate the relevance of pyroptosis and delineate its mechanisms and classifications. We also retrospectively analyze pyroptosis induced by various NMs in a broad spectrum of non-tumorous cellular environments to highlight the multifunctionality of NMs in modulating cell death pathways. We identify key knowledge gaps in current research and propose potential areas for future exploration. This review emphasizes the need to focus on less-studied areas, including the pathways and mechanisms of NM-triggered pyroptosis in non-tumor-specific cell types, the interplay between biological and environmental factors, and the interactions between NMs and cells. This review aims to encourage further investigations into the complex interplay between NMs and pyroptosis, thereby providing a basis for developing safer and more effective nanomedical therapeutic applications.
- 9 January 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1322305
Open AccessNanomaterial-induced pyroptosis: a cell type-specific perspective
This review presents the advancements in nanomaterial (NM)-induced pyroptosis in specific types of cells. We elucidate the relevance of pyroptosis and delineate its mechanisms and classifications. We also retrospectively analyze pyroptosis induced by various NMs in a broad spectrum of non-tumorous cellular environments to highlight the multifunctionality of NMs in modulating cell death pathways. We identify key knowledge gaps in current research and propose potential areas for future exploration. This review emphasizes the need to focus on less-studied areas, including the pathways and mechanisms of NM-triggered pyroptosis in non-tumor-specific cell types, the interplay between biological and environmental factors, and the interactions between NMs and cells. This review aims to encourage further investigations into the complex interplay between NMs and pyroptosis, thereby providing a basis for developing safer and more effective nanomedical therapeutic applications.
- Open Access
- 8 January 2024
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 515 (1) , 29-35
Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells
Although epigallocatechin-3-gallate (EGCG) can potentiate chemotherapeutic drugs at high concentrations, its clinical translation is hampered by exceeding possible concentration thresholds. This study proposes a dichotomous use of low-concentration EGCG in chemotherapy. During the first cycle of combined treatment with oxaliplatin (OXA), low-concentration EGCG antagonized the cytotoxic effect of OXA on colorectal cancer (CRC) cells. However, when OXA was subsequently administered, the sensitivity of CRC cells markedly increased. Although low-concentration EGCG counteracted OXA, it reduced the OXA-induced secretion of vascular endothelial growth factor by tumor cells, thereby contributing to the increase in the sensitivity of tumor cells to the second round of OXA treatment. Therefore, low-concentration EGCG showed potential as a viable adjunct to modulate chemosensitivity in CRC.
- 8 January 2024
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 515 (1) , 29-35
Open AccessDichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells
Although epigallocatechin-3-gallate (EGCG) can potentiate chemotherapeutic drugs at high concentrations, its clinical translation is hampered by exceeding possible concentration thresholds. This study proposes a dichotomous use of low-concentration EGCG in chemotherapy. During the first cycle of combined treatment with oxaliplatin (OXA), low-concentration EGCG antagonized the cytotoxic effect of OXA on colorectal cancer (CRC) cells. However, when OXA was subsequently administered, the sensitivity of CRC cells markedly increased. Although low-concentration EGCG counteracted OXA, it reduced the OXA-induced secretion of vascular endothelial growth factor by tumor cells, thereby contributing to the increase in the sensitivity of tumor cells to the second round of OXA treatment. Therefore, low-concentration EGCG showed potential as a viable adjunct to modulate chemosensitivity in CRC.
- Open Access
- 3 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1331981
Shifting the paradigm in RNA virus detection: integrating nucleic acid testing and immunoassays through single-molecule digital ELISA
In this review article, we explore the characteristics of RNA viruses and their potential threats to humanity. We also provide a brief overview of the primary contemporary techniques used for the early detection of such viruses. After thoroughly analyzing the strengths and limitations of these methods, we highlight the importance of integrating nucleic acid testing with immunological assays in RNA virus detection. Although notable methodological differences between nucleic acid testing and immune assays pose challenges, the emerging single-molecule immunoassay-digital ELISA may be applied to technically integrate these techniques. We emphasize that the greatest value of digital ELISA is its extensive compatibility, which creates numerous opportunities for real-time, large-scale testing of RNA viruses. Furthermore, we describe the possible developmental trends of digital ELISA in various aspects, such as reaction carriers, identification elements, signal amplification, and data reading, thus revealing the remarkable potential of single-molecule digital ELISA in future RNA virus detection.
- 3 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1331981
Open AccessShifting the paradigm in RNA virus detection: integrating nucleic acid testing and immunoassays through single-molecule digital ELISA
In this review article, we explore the characteristics of RNA viruses and their potential threats to humanity. We also provide a brief overview of the primary contemporary techniques used for the early detection of such viruses. After thoroughly analyzing the strengths and limitations of these methods, we highlight the importance of integrating nucleic acid testing with immunological assays in RNA virus detection. Although notable methodological differences between nucleic acid testing and immune assays pose challenges, the emerging single-molecule immunoassay-digital ELISA may be applied to technically integrate these techniques. We emphasize that the greatest value of digital ELISA is its extensive compatibility, which creates numerous opportunities for real-time, large-scale testing of RNA viruses. Furthermore, we describe the possible developmental trends of digital ELISA in various aspects, such as reaction carriers, identification elements, signal amplification, and data reading, thus revealing the remarkable potential of single-molecule digital ELISA in future RNA virus detection.
- 13 December 2023
- Published by Springer Nature in Inflammation Research
- Vol. 73 (2) , 175-181
The immunomodulatory effects of metformin in LPS-induced macrophages: an in vitro study
Objective The study aimed to explore the immunomodulatory effects of clinically relevant concentrations of metformin on macrophages during sepsis, which is characterized by an initial hyperinflammatory phase followed by a period of immunosuppression. Methods We employed the RAW 264.7 mouse macrophage cell line as an in vitro model to induce inflammatory responses and immune suppression through primary and secondary stimulation by lipopolysaccharide (LPS). The cells were exposed to clinically relevant concentrations of metformin, and their responses were gauged through cytotoxicity assays, enzyme-linked immunosorbent assay for cytokine quantification, and assessments of intracellular reactive oxygen species (ROS) production. Moreover, to probe the role of AMPK in mediating the effects of metformin, we conducted an AMP-activated protein kinase (AMPK) activity assay and knocked down AMPK using siRNA. Results Our study revealed that clinically relevant concentrations of metformin considerably decreased the LPS-induced secretion of tumor necrosis factor-α and interleukin-6, which indicates the suppression of the initial hyperinflammatory response. Furthermore, metformin prevented LPS-induced immunosuppression. Notably, these immunomodulatory effects of metformin were not mediated by the activation of the AMPK pathway, as evidenced by the unaltered AMPK activity and siRNA experiments. The modulation of intracellular ROS levels emerged as the critical mechanism underlying the inhibition of hyperinflammation and impediment of immunosuppression by metformin. Conclusion A certain therapeutic dose of metformin inhibited hyperinflammatory responses and alleviated immunosuppression in LPS-induced macrophages through the bidirectional modulation of intracellular ROS generation.
- 13 December 2023
- Published by Springer Nature in Inflammation Research
- Vol. 73 (2) , 175-181
The immunomodulatory effects of metformin in LPS-induced macrophages: an in vitro study
Objective The study aimed to explore the immunomodulatory effects of clinically relevant concentrations of metformin on macrophages during sepsis, which is characterized by an initial hyperinflammatory phase followed by a period of immunosuppression. Methods We employed the RAW 264.7 mouse macrophage cell line as an in vitro model to induce inflammatory responses and immune suppression through primary and secondary stimulation by lipopolysaccharide (LPS). The cells were exposed to clinically relevant concentrations of metformin, and their responses were gauged through cytotoxicity assays, enzyme-linked immunosorbent assay for cytokine quantification, and assessments of intracellular reactive oxygen species (ROS) production. Moreover, to probe the role of AMPK in mediating the effects of metformin, we conducted an AMP-activated protein kinase (AMPK) activity assay and knocked down AMPK using siRNA. Results Our study revealed that clinically relevant concentrations of metformin considerably decreased the LPS-induced secretion of tumor necrosis factor-α and interleukin-6, which indicates the suppression of the initial hyperinflammatory response. Furthermore, metformin prevented LPS-induced immunosuppression. Notably, these immunomodulatory effects of metformin were not mediated by the activation of the AMPK pathway, as evidenced by the unaltered AMPK activity and siRNA experiments. The modulation of intracellular ROS levels emerged as the critical mechanism underlying the inhibition of hyperinflammation and impediment of immunosuppression by metformin. Conclusion A certain therapeutic dose of metformin inhibited hyperinflammatory responses and alleviated immunosuppression in LPS-induced macrophages through the bidirectional modulation of intracellular ROS generation.
- 1 April 2023
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 509 (1) , 81-85
Fucoxanthin Alleviates Lipopolysaccharide-Induced Inflammation and Immunosuppression in RAW264.7 Macrophages
Fucoxanthin (FX) has been reported to reduce mortality in mouse models of sepsis, but its exact cause remains to be determined. In the present study, we evaluated the immunomodulatory properties of FX in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. Our results showed that FX could not only suppress the immune activation responses caused by LPS primary stimulation, but also antagonize LPS restimulation-induced immunosuppression in macrophages. The immunomodulatory capabilities of FX was mainly demonstrated by regulating the production of the inflammatory mediator under different LPS stimuli. Furthermore, we found that adenosine monophosphate-activated protein kinase (AMPK) activation was required for FX’s anti-inflammatory and anti-immunosuppressive activities. Our results complement existing data supporting the clinical potential for FX in treating sepsis.
- 1 April 2023
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 509 (1) , 81-85
Fucoxanthin Alleviates Lipopolysaccharide-Induced Inflammation and Immunosuppression in RAW264.7 Macrophages
Fucoxanthin (FX) has been reported to reduce mortality in mouse models of sepsis, but its exact cause remains to be determined. In the present study, we evaluated the immunomodulatory properties of FX in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. Our results showed that FX could not only suppress the immune activation responses caused by LPS primary stimulation, but also antagonize LPS restimulation-induced immunosuppression in macrophages. The immunomodulatory capabilities of FX was mainly demonstrated by regulating the production of the inflammatory mediator under different LPS stimuli. Furthermore, we found that adenosine monophosphate-activated protein kinase (AMPK) activation was required for FX’s anti-inflammatory and anti-immunosuppressive activities. Our results complement existing data supporting the clinical potential for FX in treating sepsis.